Here's the Latest on Four New Biotech IPOs

Here's the Latest on Four New Biotech IPOs


The iShares Nasdaq Biotechnology ETF hit almost 10% over the past month following an announcement from the New York Times that the Trump administration plans to ease regulatory red tape within the drug industry rather than lower drug prices. And given the proliferation of IPO launches, it appears that biotech and pharmaceutical companies have caught whiff of the news.



from Biotech News